Literature DB >> 29128273

Epidemiological and clinical characteristics of humans with avian influenza A (H7N9) infection in Guangdong, China, 2013-2017.

Yuwei Yang1, Haojie Zhong1, Tie Song1, Jianfeng He1, Lan Guo2, Xiaohua Tan1, Guofeng Huang1, Min Kang3.   

Abstract

OBJECTIVE: To describe the demographics and clinical characteristics of patients with A (H7N9) infection, to test the differences in the distribution of demographics and clinical characteristics by clinical severity, and to explore potential factors associated with clinical severity.
METHODS: This retrospective study was conducted to collect epidemiological and clinical information regarding the confirmed cases in Guangdong through field investigation and review of medical records.
RESULTS: Of the 256 cases, 100 (39.0%) patients died, and 168 (65.6%) patients were admitted to ICUs. The male-to-female ratio was approximately 2.0:1, and the median age was 56 years (range, 1 to 88). Among the 215 patients accepting oseltamivir treatment, the median time from the onset of illness to oseltamivir treatment was 5days (range, 0 to 16); 35 patients received zanamivir treatment after a median of 8days (range, 0 to 23). The univariable logistic regression models demonstrated that time from the onset of illness to oseltamivir treatment (OR=1.10, 95% CI=1.01-1.10) and zanamivir treatment (OR=1.05, 95% CI=1.02-1.07) were associated with the death of patients.
CONCLUSIONS: Preventive measures should focus on high-risk populations, such as the elderly and the groups with high frequency exposure to live poultry. Earlier oseltamivir and zanamivir treatment were recommended.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Avian influenza; Clinical characteristics; Epidemiological characteristics; H7N9 subtype

Mesh:

Substances:

Year:  2017        PMID: 29128273     DOI: 10.1016/j.ijid.2017.07.021

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  Factors Associated With Fatality Due to Avian Influenza A(H7N9) Infection in China.

Authors:  Shufa Zheng; Qianda Zou; Xiaochen Wang; Jiaqi Bao; Fei Yu; Feifei Guo; Peng Liu; Yinzhong Shen; Yimin Wang; Shigui Yang; Wei Wu; Jifang Sheng; Dhanasekaran Vijaykrishna; Hainv Gao; Yu Chen
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

2.  Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.

Authors:  Patricia Winokur; Hana M El Sahly; Mark J Mulligan; Sharon E Frey; Richard Rupp; Evan J Anderson; Kathryn M Edwards; David I Bernstein; Kenneth Schmader; Lisa A Jackson; Wilbur H Chen; Heather Hill; Abigail Bellamy
Journal:  Vaccine       Date:  2021-01-21       Impact factor: 3.641

3.  Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform.

Authors:  Masafumi Endo; Mitsuyoshi Tanishima; Kayo Ibaragi; Kenshi Hayashida; Tadashi Fukuda; Tetsuro Tanabe; Takeshi Naruse; Yoichiro Kino; Kohji Ueda
Journal:  Influenza Other Respir Viruses       Date:  2020-06-24       Impact factor: 4.380

4.  Impacts of age and gender at the risk of underlying medical conditions and death in patients with avian influenza A (H7N9): a meta-analysis study.

Authors:  Qinglin Cheng; Gang Zhao; Li Xie; Xuchu Wang
Journal:  Ther Clin Risk Manag       Date:  2018-09-06       Impact factor: 2.423

5.  Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans.

Authors:  Junbo Chen; Huachen Zhu; Peter W Horby; Qianli Wang; Jiaxin Zhou; Hui Jiang; Liwei Liu; Tianchen Zhang; Yongli Zhang; Xinhua Chen; Xiaowei Deng; Birgit Nikolay; Wei Wang; Simon Cauchemez; Yi Guan; Timothy M Uyeki; Hongjie Yu
Journal:  J Infect       Date:  2020-01-16       Impact factor: 38.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.